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Objective:
 
 In this study, we modify previously published
models to estimate the short- and long-term consequences
of nevirapine triple combination therapy use in five de-
veloped countries. Current pharmacoeconomic practice
requires the de novo model development for each new
therapy comparison. This approach is lengthy and costly,
and it may yield models with very different structures.
Standardized, detailed disclosure of model assumptions
and parameters makes it possible to recycle published
models with minor structural modifications to examine
the efficiency of therapies based on new trial data.
 
Methods:
 
 Two well-publicized models of HIV therapy
are modified to fit new trial data comparing double and
triple combination therapy with nevirapine; model pa-
rameters are adjusted to represent clinical practice and
cost structure in five countries. A short-term model uses
trial data from advanced-stage patients to estimate first-
year costs and consequences. A long-term model uses
data from antiretroviral-naïve patients to estimate long-
term cost-effectiveness.
 
Results:
 
 During the first year, for each 100 individuals
treated with nevirapine triple combination therapy, 2.7
deaths and 30.8–31.4 opportunistic disease events would
be averted compared to employing dual therapy. Addi-
tionally, 61% to 142% of the first-year costs of nevirap-
ine therapy would be offset by other medical care costs
 
savings [FF19,749, DM3,778, 3334 (
 

 
1000) lire, 293
(
 

 
1000) ptas, and US $3,569]. Compared to dual com-
bination therapy, nevirapine triple combination therapy
is predicted to yield incremental cost-effectiveness ratios
(discounted at 3%) of FF101,057, DM30,709, 28,066
(
 

 
1000) lire, 1294 (
 

 
1000) ptas, and US $14,338.
 
Conclusion:
 
 Published, well-constructed, and docu-
mented cost-effectiveness models can be reused to esti-
mate the economic impact of therapies for HIV disease.
Such models can also be used to provide insight into the
factors that affect efficiency across countries. Our use
of clinical trial data on nevirapine, together with pub-
lished HIV economic models, provides support for the
hypothesis that nevirapine is cost-effective under the
cost structures of five developed countries.
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Introduction
 
Currently three classes of antiretroviral drugs are
available for the treatment of HIV/AIDS, provid-
ing physicians and patients with a number of
promising options for the control of the virus.
These new combinations of drugs, together with
improved monitoring capability, allow the physi-
cian to customize drug therapy to reflect the pa-
tient’s viral load, level of immunosuppression,
preferences for treatment, previous drug toxicities,
and resistance. Antiretroviral therapies, employed
in double or triple combinations, can control viral
replication, diminish CD4 cell count depletion,
and slow the progression of the disease [1]. How-
ever, rapid viral mutation [2,3] results in these
therapies being effective only for limited periods
until eventually viral replication begins anew. Re-
cent consensus panels recommend that potent
combination therapy be employed early in the dis-
ease process to reduce the viral load to below the
level of quantitation [4,5]. Furthermore, these
groups suggest that alternative therapy combina-
tions, dictated by drug interactions, previous ther-
apy, and crossresistance patterns, must be employed
and revised as viral breakthrough or development
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of resistance occurs or as a result of physician
judgment or patient preferences.
Recently completed and ongoing clinical trials
[6,7] demonstrate that nevirapine in combination
with zidovudine (ZDV) and didanosine (ddI) can
slow further destruction of the immune system
compared with ZDV and ddI dual combination
therapy, adding an important new weapon against
the human immunodeficiency virus. Extended fol-
low-up of individuals receiving this therapy re-
vealed that more than 64% of those still taking
the drug combination after 2 years maintained vi-
ral loads below the level of quantitation [8]. These
results suggest that nevirapine triple combination
therapy may play an important role in the HIV/
AIDS therapy sequence.
The cost of care for individuals with HIV/AIDS
is high, and resources to pay for this care are in-
creasingly scarce [5]. This is especially true for an-
tiretroviral therapy budgets, because of the large
number of effective drugs that have entered the
market recently, and because study results indicate
that combination therapy is the only effective ap-
proach to controlling the virus [4]. Patients, physi-
cians, third-party payers, and governments must
look for evidence that new drugs and drug combi-
nations provide good value for money. To assess
the value of a new or alternative drug combina-
tion, decision-makers balance the maintenance of
health and the reduction in costs associated with
avoiding hospital admissions and opportunistic
disease against increases in drug acquisition costs
for new or alternative therapy combinations. This
assessment should focus on both the short-term
(i.e., first-year costs) and the longer-term (i.e.,
over the expected lifetime of a cohort of individu-
als). Although many drug trials have begun to col-
lect costs and resource use (i.e., drugs, clinic visits,
hospital admissions) data, this is not yet the norm
(or standard practice) and such data are absent for
many promising drug combinations. In the ab-
sence of these data, it is necessary to combine
available clinical trial data with cost-effectiveness
models to estimate the added value of new drugs
and combinations [9].
Over the past decade, a number of researchers
have presented [10–12] or published [13–17]
models estimating the health benefits and eco-
nomic costs associated with HIV drug therapy.
These models have examined short-term [12,17]
or long-term [10,11,13–16,18] costs and health
benefits, but not both. Additionally, only Simpson
et al. [15] and Kempel et al. [11] make cross-
national comparisons.
These published models provide more than just
a valuable contribution to our understanding of
the relationship between two or more individual
therapies and the economic efficiency of care; they
also capture the essence of the health production
process for antiretroviral therapy in general. They
do this by specifying the known relationship be-
tween prognostic indicators (e.g., CD4 cell count
or viral load) and health outcomes (i.e., events
or death) based on population data. In addition,
they estimate the cost of care provided for a well-
described patient group under specific conditions
(e.g., for a country or for a provider system within
a country). The practice in the field of health eco-
nomics has been to develop a model de novo for
each therapy comparison. However, this approach
is lengthy and costly, and it has the disadvantage
that the model structures often vary across studies.
The move toward standardized, detailed disclo-
sure of model assumptions and parameters makes
it possible to recycle some published models with
only minor structural modifications to examine
the efficiency of therapies based on new trial data.
The objective of this study was to compare nev-
irapine triple combination therapy to dual combi-
nation therapy in five developed countries. We
take two well-publicized models [15,16], modify
them to fit the new trial data (i.e., data from each
of two clinical trials), and adjust the model pa-
rameters to represent the clinical practice and
medical care cost structures in these countries. The
strength of this approach is that it is frugal, avoids
inserting the author’s biases into the model’s struc-
ture, and allows parsimonious descriptions of models
that are quite complex. The weaknesses of the ap-
proach are that the therapeutic effects evidenced
in the trial reports may not be captured with suffi-
cient fidelity because the models were not de-
signed specifically for these trials, and that the
modifications to the model parameters made may
run counter to unspecified structural assumptions
embedded in the original models.
 
Methods
 
Country-specific differences in disease epidemiol-
ogy, treatment patterns, and resource utilization
indicate that it is important to assess a new or al-
ternative therapy within the country-specific envi-
ronment to determine its potential value or contri-
bution in that location. Additionally, assessments
of the same therapy in several countries provide
evidence of the extent to which a therapy can add
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value, to different degrees, depending upon coun-
try-specific parameters.
Here, two modeling approaches (each used
with one specific set of trial data) are used to pre-
dict the short- and long-term economic perfor-
mance of nevirapine triple combination therapy in
five countries—France, Germany, Italy, Spain, and
the United States. The first model uses data from a
trial of advanced-stage patients to estimate the
first-year drug acquisition costs compared with
the reduction in healthcare costs (e.g., costs of
hospitalization, clinic visits, specialist consults) as-
sociated with opportunistic disease events averted.
The second model uses trial data from antiretro-
viral-naïve patients to estimate the lifetime cost-
effectiveness of nevirapine triple combination ther-
apy, compared with dual therapy without nevirapine,
assuming subsequent treatment with protease in-
hibitor combinations.
 
Modeling the First-Year Health Benefits and Costs of 
Nevirapine Triple Therapy
Model Description and Structure.
 
The Simpson
et al. [15] model was modified to evaluate the
first-year impact of using nevirapine triple combi-
nation therapy compared to dual drug therapy.
The original model was specifically designed to ac-
commodate local epidemiological patterns and
variations in AIDS clinical practice patterns in
North America and several European countries. In
the current application, this model is well suited
for three reasons:
1. It is possible to adjust for differences in the en-
vironmentally related risk of specific opportu-
nistic disease events (ODEs; e.g., rate of posi-
tive titer for toxoplasmosis) by comparing the
model’s base incidence assumptions for ODEs
to the epidemiological reports for a particular
country.
2. By changing treatment algorithms to reflect a
prespecified set of treatment patterns for acute
and chronic clinical events until they reflect
those of a specific country, it is possible to ad-
just for country-specific treatment practices.
3. Country-specific input price differences are re-
flected by using unit cost values for a large set
of key cost drivers in HIV management (e.g.,
drugs, visits, hospital costs) that best reflect
current opportunity cost.
Simpson et al. [15] use a Markov process to link
disease stage, as measured by level of immunosup-
pression, to risk of opportunistic disease events
 
(Fig. 1). Opportunistic disease events are subse-
quently linked to resource use (e.g., diagnostic tests,
drugs, clinic visits, specialist consults, hospitaliza-
tion days) and cost. In the first stage of the model,
a patient cohort is classified into six mutually ex-
clusive opportunistic disease event risk categories
by level of immune suppression (as measured by
CD4 cell count in cells/mm
 
3
 
)—
 

 
50, 50–99, 100–
149, 150–199, 200–299, and 
 

 
300. Risk is mea-
sured by the geometric mean of the CD4 cell de-
cline curve for a 60-day period from appropriate
clinical trial data. Eight vectors of ODE probabil-
ity density estimates, derived from published epi-
demiological data fitting these risk groups, are used
to estimate the expected number of HIV-related
events per year. These event groups—Pneumocys-
tis carinii pneumonia, toxoplasmic encephalitis,
Mycobacterium avium complex, cryptococcal men-
ingitis, severe Kaposi’s sarcoma, cytomegalovirus
(CMV) retinitis, lymphoma, and tuberculosis—are
those most frequently seen in AIDS.
To assign resource use and costs to the annual
estimates of ODEs, a set of standard treatment al-
gorithms was adjusted in the original model devel-
opment by Simpson et al. [15] by experienced
physicians to reflect the local practice patterns in
each of the five countries. Country-specific input
prices for diagnostic tests, drugs, clinic visits, spe-
cialist consults, hospital ward days, intensive care
unit (ICU) days, diagnostic procedures, and cura-
tive/palliative procedures were combined with the
treatment algorithms to derive the average costs of
care for each ODE. Simpson et al. [15] provide ad-
ditional information concerning the modeling, treat-
ment algorithm development, and cost estimation
processes.
To use the nevirapine clinical trial data several
modifications of the Simpson et al. [15] model
were required. First, the model was truncated after
1 year; instead of extrapolating long-term sur-
vival, the model was used to predict only events
and costs for the first year of therapy. Simpson
and LaVallee [12] performed a similar model trun-
cation to describe the first-year impact of saquinavir
triple combination therapy. The model described
here reports treatment impacts in terms of annual
ODEs and deaths and costs of medical care. Sec-
ond, ODEs were expanded to capture more com-
prehensively the spectrum of AIDS-related disease,
allowing for the inclusion of such conditions as
bacterial pneumonia, wasting syndrome, AIDS de-
mentia, and nonspecific infections. The ODEs in-
cluded in the modified model are 1) Pneumocystis
carinii pneumonia; 2) toxoplasmic encephalitis; 3)
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Mycobacterium avium complex; 4) cryptococcal
meningitis; 5) cytomegalovirus (CMV) retinitis and
other CMV disease; 6) central nervous system lym-
phoma and non-Hodgkin’s lymphoma; 7) severe
Kaposi’s sarcoma; 8) chronic Herpes simplex virus
infection; 9) Candida esophagitis; and 10) other
acute events (rehydration for wasting syndrome,
cryptosporidiosis, neurological workup for HIV
encephalopathy, bacterial pneumonia, severe/multi-
drug-resistant tuberculosis, terminal care).
During the period of 1 year, the modified
model follows two hypothetical cohorts of 100
patients who receive either nevirapine triple com-
bination therapy or ZDV/ddI dual therapy. An-
nual ODEs and deaths are estimated during the
modeling process by simulating the risk of devel-
oping 1 of the 10 specific events during each of six
2-month cycles. During a 2-month cycle, individu-
als remain well, die, or experience one of the
events. Individuals who remain well during a cycle
begin the subsequent model cycle in the risk cate-
gory that matches their CD4 cell counts at the be-
ginning of that cycle. At the end of the year, the
expected number of ODEs, deaths, and costs are
summed across the cycles to obtain annual esti-
mates for both the triple and dual therapy treat-
ment arms.
 
Data Sources.
 
The input parameters for the model
are presented in Tables 1 and 2. From a short-term
economic perspective, it is necessary to model a
population that is broadly representative of the en-
tire HIV disease population in each of the five
countries. The population of the AIDS Clinical
Trial Group (ACTG) 241 trial, adults with HIV in-
fection who had CD4 cell counts of 
 

 
350 cells/
mm
 
3
 
 and who had at least 6 months of prior treat-
ment with nucleoside reverse transcriptase inhibi-
tors [6], is quite representative of patients likely to
be treated with nevirapine triple combination ther-
apy in the countries of interest. The 2-month risk of
ODEs and death were estimated from the 52-week
CD4 cell count data from ACTG 241 [6] (Table 1).
The CD4 cell count distribution was estimated
for each 2-month period; when two or more mea-
surements were reported for a 2-month period, the
Figure 1 This figure provides a schematic representation of the Simpson et al. [15] model. Modifications required for use with
the ACTG 241 clinical trial data are indicated by an asterisk. PCP, Pneumocystis carinii pneumonia; MAC, Mycobacterium
avium complex; KAPOSI, Kaposi’s sarcoma; CRYPTO, cryptococcal meningitis; CMV, cytomegalovirus retinitis and other CMV
disease; LYMPHO, central nervous system and non-Hodgkin’s lymphoma; HERPES, chronic herpes simplex virus infection;
CANDIDA, Candida esophagitis; TOXO, toxoplasmosis meningitis; OTHER, other acute events (rehydration for wasting syn-
drome or cryptosporidiosis, neurologic workup for HIV encephalopathy, bacterial pneumonia, severe/multi-drug-resistant tu-
berculosis, terminal care); ODE, opportunistic disease event; LC, local currency (French francs, German deutschemarks, Italian
lire, Spanish pesetas, United States dollars).
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mean CD4 cell count was calculated and subse-
quently used to obtain the distribution. Prelimi-
nary analyses revealed a predicted maldistribution
of economic costs between the two treatment arms
resulting from slight imbalances in the baseline
distribution of patients with very low CD4 cell
counts. This imbalance, though not representing
clinical bias, results in the overrepresentation of
the risk of high-cost ODEs. Indirect adjustment
techniques [19] were required to quantify and to
equalize the economic bias at baseline between the
two treatment arms. First, the results for the dual
 
Table 1
 
Baseline CD4 cell counts and risks of opportunistic disease events and death for the short-term model of nevirapine 
triple combination therapy, by country, 1997
 
Model parameter Value Source
Baseline CD4 cell count (cells/mm
 
3
 
) (%) ZDV 
 

 
 ddI NVP 
 

 
 ZDV 
 

 
 ddI [6]
 

 
50 25.4 21.3
50–99 13.4 12.7
100–149 13.4 18.8
150–199 11.4 9.1
200–299 25.9 26.9
Annual risk of opportunistic disease events and death (%)* France/Germany Italy/Spain United States [12,15,20]
Pneumocystis carinii pneumonia 12.8 12.8 12.8
Mycobacterium avium complex 14.8 14.8 18.0
Kaposi’s sarcoma 15.1 15.1 15.1
Cryptococcal meningitis 1.4 1.4 1.4
Cytomegalovirus (CMV) retinitis and other CMV disease 25.5 25.5 25.5
Candida esophagitis 9.9 9.9 9.9
Chronic Herpes simplex virus infection 35.3 35.3 35.3
Lymphoma 2.4 2.4 2.4
Toxoplasmic encephalitis 2.4 4.8 2.4
Other events 40.0 40.0 40.0
Death by CD4 count (cells/mm
 
3
 
) (%)
 

 
50 22.6 [21]
50–99 11.9
100–149 6.0
150–199 1.8
 
*Totals may not add to 100.0% because of rounding.
ddl, didanosine; NVP, nevirapine; ZDV, zidovudine.
 
Table 2
 
Costs of opportunistic disease events in 1997, by country
 
Germany (DM)
 
†
 
Italy (
 

 
1000 lire)
 
‡
 
Opportunistic disease event France (FF)* Base case Spanish rates Spain (ptas)
 
†
 
US (US$)
 
§
 
Pneumocystis carinii pneumonia 76,485 4,566 8,846 11,146 878,499 8,481
Mycobacterium avium complex 99,499 21,692 20,417 36,546 1,909,387 8,738
Kaposi’s sarcoma 64,729 2,712 3,561 3,309 347,991 5,400
Cryptococcal meningitis 105,170 23,166 36,665 31,072 2,249,207 16,988
Cytomegalovirus retinitis 106,271 56,942 37,688 42,964 3,288,098 51,987
Candida esophagitis 59,342 526 926 584 445,448 1,495
Herpes 59,342
 

 
1,603 781 1,484 221,107 437
Lymphoma 83,789 21,468 23,546 20,022 2,001,722 13,197
Toxoplasmic encephalitis 76,875 24,434 12,131 7,620 1,834,551 14,483
Other events 76,485 4,566 8,846 7,977 571,273 8,217
 
*Simpson and LaVallee [12].
 
†
 
Kempel et al. [22].
 
‡
 
Base case uses Italian DRG costs as inputs to the cost algorithms of Simpson and LaVallee [12]. These cost algorithms were modified to reflect admissions rates
identical to those reported in Spain.
 
§
 
Brown et al. [23].
 

 
The cost of herpes is not reported by Kempel et al. [23]. Because the treatment for herpes and candidiasis are similar, the costs of care for herpes are assumed to
be identical to those for Candida esophagitis.
Cost figures reported in 1997 local currency. Cost figures were inflated using the country-specific All-Items Consumer Price Index reported by the Organization
for Economic Cooperation and Development Main Economic Indicators [39] or, in the case of the United States, the Medical Care Component of the Consumer
Price Index [40].
Cytomegalovirus retinitis, Cytomegalovirus (CMV) retinitis and other CMV disease; Herpes, chronic Herpes simplex virus infection; Lymphoma, central nervous
system lymphoma and non-Hodgkin’s lymphoma; Other events, other acute events (rehydration for wasting syndrome or cryptosporidiosis, neurologic workup for
HIV encephalopathy, bacterial pneumonia, severe/multi-drug-resistant tuberculosis, terminal care); FF, French francs; DM, German deutschemarks; lire, Italian lire;
ptas, Spanish pesetas; US$, United States dollars.
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therapy arm were estimated separately for patients
in each of the model’s risk strata (based on their
baseline CD4 values). Next, using the baseline
CD4 cell count distribution of the patients in the
nevirapine triple therapy arm as weights, the
weighted means for all events (ODEs and deaths)
and costs were calculated. However, this approach
increases the risk of redistributing unknown bias-
ing factors while removing the known bias that
occurred during randomization. Consequently, both
unadjusted and adjusted results are reported.
The risks of ODEs and death (Table 1) were es-
timated using four data sources [12,15,20,21].
The country-specific risks of ODEs estimated by
Simpson et al. [15] were employed for the French,
German, Italian, and American models. Spain was
not included in the original Simpson et al. [15]
model; therefore, risk data were derived from the
later Simpson and LaVallee [12] model. To reflect
epidemiological differences between the five coun-
tries, the incidence rates for toxoplasmic encepha-
litis and Mycobacterium avium complex were ad-
justed using the data of Bacellar et al. [20]. The
risk of death is based on a survival analysis of 289
men with CD4 cell counts 
 

 
100 cells/mm
 
3
 
 [21].
For each of the five countries, the risk of “other
events” is based on the clinical judgments of the
physician consultants used in Simpson and La-
Vallee’s [12] model of the effect of saquinavir tri-
ple combination therapy.
The cost perspective from the original model
[15] was retained. This model estimates the com-
bined factor costs to all payers—whether these di-
rect medical care costs are paid by an insurer, a
health authority, or the patient, or absorbed as
bad debt by a provider. Standard cost estimates
for the treatment of ODEs were derived from
three sources [12,22,23]. These data do not reflect
the health system reforms undertaken in Italy
since late 1995, and it was necessary to reestimate
treatment costs using available diagnosis-related
group (DRG) costs (personal communication, Boeh-
ringer Ingelheim Italia s.p.a., January 1998). How-
ever, because the Italian DRGs do not correspond
directly to all of the ODEs used in the current
model, and because, in some cases, the DRGs may
include conditions that are not always AIDS re-
lated, the costs reported may yet underestimate
the actual costs of providing care. To address this
issue, an alternative set of cost estimates was de-
veloped by assuming that disease epidemiology
and treatment patterns are similar in Italy and
Spain. To estimate these alternative costs, the Ital-
ian care algorithms and unit costs developed by
Simpson and LaVallee [12] were modified to in-
corporate Spanish hospital admission rates for
each of the ODEs. The impact of these alternative
costs is tested using sensitivity analysis. The coun-
try-specific costs are reported in Table 2. The
daily dosage of two 200-mg nevirapine tablets is
assumed to be identical across the five countries.
Per-tablet prices were obtained from Boehringer
Ingelheim GmbH (personal communication, 12
December 1997). Daily costs of nevirapine are
US$6.88, FF49, DM12.85, 15,000 lire, and
1089.15 ptas.
 
Modeling the Long-Term Cost-Effectiveness of 
Nevirapine Triple Combination Therapy
 
The model published by Chancellor et al. [16] was
modified to estimate the long-term health benefits
and economic costs of adding nevirapine to ZDV/
ddI dual combination therapy. As originally for-
mulated, the Chancellor et al. [16] model employs
a Markov process that follows a patient cohort as
it progresses through four health states—CD4 cell
count 
 

 
200 and 
 

 
500 cells/mm
 
3
 
 and no AIDS
(High CD4), CD4 
 

 
200 cells/mm
 
3
 
 and no AIDS
(Low CD4), AIDS, and death (Fig. 2). The modifi-
cation of the model that was employed was re-
quired to 1) more closely model recommended
treatment practices; and 2) accommodate avail-
able nevirapine clinical trial data.
In actual clinical practice, and according to cur-
rent treatment recommendations [4,5], patients
are switched to subsequent therapies as viral break-
through or development of resistance occurs or as
a result of physician judgment or patient prefer-
ence. The structure of the Chancellor et al. [16]
model assumes no therapy revision over the model’s
duration. The modified model is structured to re-
flect clinical practice and recommendations by as-
suming that drug therapy is revised as viral break-
through occurs. Subsequent to viral breakthrough,
nevirapine triple combination therapy or ZDV/ddI
dual combination therapy is replaced in succession
by one of two sequences of a protease inhibitor
combined with two nucleoside reverse transcrip-
tase inhibitors.
The Chancellor et al. [16] model captured
treatment differences by using the risk ratio from
a meta-analysis of specific clinical events observed
for patients in a group of clinical trials to adjust
transition probabilities between the health states.
The available nevirapine clinical trial data could
not be employed in this way because many nevi-
rapine trials have only reported surrogate marker
results to date. In the model presented here, surro-
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gate marker responses, as measured by 4- to 8-
week mean CD4 cell increases and mean time for
return of CD4 cell count to baseline, were em-
ployed to capture the difference in risk of progres-
sion between the two treatments. The transition
probabilities between the health states in the model
were reduced by this difference in risk. To accom-
modate the nevirapine trial data for patients in the
early stages of HIV infection, it was necessary to
add a fifth health state, CD4 
 

 
 500, to capture the
small number of patients whose 4- to 6-week CD4
cell increase would move them beyond the 500
cells/mm
 
3
 
 upper boundary of the Chancellor et al.
[16] High CD4 health state. Also required was a
one-time transition into this state from the High
CD4 state (and a corresponding shift from the
Low CD4 state to the High CD4 state). The tran-
sition from the CD4 
 

 
 500 state back to the High
CD4 state captured the median time at which pa-
tients return to baseline as reported in the trials.
As currently structured the modeling process
follows two cohorts of 100 individuals for about
15 years (15 1-year cycles), or until 75% of the
cohort members have died. Although Chancellor
et al. [16] employ a 20-year time horizon, a
shorter period has been selected to reflect a more
realistic time horizon for survival therapy deci-
sion-making. One group receives triple combina-
tion therapy with nevirapine, ZDV, and ddI; the
other receives dual combination therapy of ZDV
and ddI. The total life expectancy for the treat-
ment cohorts is calculated by summing the ex-
pected number of years spent in each of the four
living health states. The expected number of years
spent in a particular health state is calculated by
summing the total number of person-years spent
in a particular health state and dividing by the co-
hort size. The expected total costs for each treat-
ment is calculated by multiplying the number of
years that patients spend in each of the four living
states by the health-state-specific care costs. The
incremental cost-effectiveness ratio (reported in
local currency per year of life saved) is calculated
by dividing the total cost difference (i.e., medical
care and antiretroviral drug costs) by the differ-
ence in survival.
 
Data Sources.
 
Treatment effect duration data are
provided in Table 3. INCAS 1046 trial data were
used to derive the treatment effects and duration
for the nevirapine triple combination and ZDV/
ddI dual combination therapies [7]. This popula-
tion of AIDS-free, antiretroviral-therapy-naïve adults
(CD4 cell count range: 200–600 cells/mm
 
3
 
) was
selected because it best reflects current recommen-
dations for early initiation of antiretroviral ther-
apy [4,5]. The annual transition probabilities from
the Chancellor et al. [16] model were modified as
follows. To account for the 100-cell/mm
 
3
 
 increase
that is expected to result from nevirapine triple
combination therapy (52-week INCAS 1046 data)
[7], a proportion of the upper 50% of individuals
in the Low CD4 and High CD4 cell states is as-
sumed to progress upward into the next highest
categories—High CD4 and CD4 
 

 
 500, respec-
tively. For example, a 100-cell increase would
Figure 2 This figure provides a schematic
representation of the Chancellor et al. [16]
model indicating modifications required by
the INCAS 1046 trial data. The dashed box
indicates a new health state that was added
to accommodate the data; the X indicates
a state transition that was eliminated as a
result of the available nevirapine trial data.
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move those with CD4 cell counts 
 

 
100 but 
 

 
200
cells/mm
 
3
 
 (i.e., Low CD4) into the High CD4 cell
category; a similar increase would move those
High CD4 individuals with CD4 counts of 400
cells/mm
 
3
 
 and higher into the CD4 
 

 
 500 cate-
gory. For individuals in the CD4 
 

 
 500 health
state, the transition probability back to the High
CD4 state is assumed to be 50% lower during the
subsequent model cycle [24]. The CD4 cell in-
crease is assumed to occur during the first quarter
and to slowly decline, returning to baseline within
the time frame indicated in the trial data. A similar
approach was taken for the comparison arm but
the transition back to baseline was assumed to be
faster. This may bias our estimates slightly against
nevirapine.
Median time to viral breakthrough subsequent
to nevirapine triple therapy and ZDV/ddI dual
therapy are assumed to be 24 months and 15
months, respectively, after therapy initiation [7].
The model assumes a 100-cell increase in CD4 cell
count and that viral breakthrough occurs at 18
months for the first protease inhibitor combina-
tion. Clinical trials evaluating the duration of viral
suppression for protease inhibitors are ongoing
with only preliminary results available [25–28].
However, the results of one trial indicates that at
100 weeks, 69% of individuals receiving triple
therapy with indinavir, lamivudine, and zidovu-
dine had viral levels measuring 
 

 
50 copies per ml
[26]. This suggests that 18-month assumption
may be somewhat conservative. Because recent
clinical trials [29–33] suggest that viral break-
through for subsequent protease inhibitor combi-
nations occurs earlier and results in less of a CD4
cell count increase in protease-inhibitor-experi-
enced individuals, viral breakthrough for the sec-
ond combination is assumed to occur at 15 months
with a CD4 cell response seen only in 90% of pa-
tients.
Each of the two protease inhibitor combina-
tions used after initial viral breakthrough includes
one protease inhibitor and two nucleoside reverse
transcriptase inhibitors. These combinations com-
pose a composite of the existing protease inhibitor
combinations, reflecting the proportion of use of
highly active antiretroviral therapy (HAART) ther-
apies currently recommended in centers of excellence
[34]. The nucleoside reverse transcriptase inhibitor
mix is derived by weighting the proportion of use
and length of time of expected use for each combi-
nation, given what is currently understood about
patterns of overlapping resistance [4,32,35,36].
Like the original Chancellor et al. [16] model,
the long-term cost-effectiveness model employs
the perspective of the healthcare system to enu-
merate costs. Country-specific health state and
drug therapy costs are presented in Table 4. Be-
cause the Chancellor et al. [16] health-state-spe-
cific cost data are available only for the United
Kingdom, it was necessary to calculate an AIDS-
specific cost conversion factor to translate costs
for each of the five country-specific models de-
scribed here. To maintain consistency in cost esti-
mation between the two models, we used data
from the short-term model described earlier for
this calculation. This conversion factor was calcu-
lated by dividing the weighted cost of care for
AIDS events in each of the five countries by the
average weighted cost of care for patients in the
United Kingdom reported by Simpson and La-
Vallee [12]. The United Kingdom health-state-spe-
cific cost data reported by Chancellor et al. [16]
then were multiplied by these AIDS-specific con-
version factors, producing estimates (in local cur-
rency) of the country-specific cost of care for each
health state.
The costs of the protease inhibitor combina-
tions are a weighted average of the country-spe-
cific ex-factory prices of these combinations (personal
communication, Boehringer Ingleheim, January–
 
Table 3
 
Input parameters for the lifetime
cost-effectiveness model, 1997
 
Model parameter Value Source
Estimated duration of
effect (in months)
ZDV 
 

 
 ddI 15 [7]
NVP 
 

 
 ZDV 
 

 
 ddI 24 [7]
First protease inhibitor
combination 18 [25–28]
Second protease
inhibitor combination 15 [30–34]
Weighting* factors (%)
US/
France
Germany/
Italy/Spain
Protease inhibitors [34]
Indinavir 30 33.3
Nelfinavir 30 —
 
†
 
Ritonavir 20 33.3
Saquinavir 20 33.3
NRTIs [4,32,35,36]
Zidovudine 25
Lamivudine 20
Didanosine 25
Zalcitabine 15
Stavudine 10
 
*The weights reflect the proportion of use, and they are combined with coun-
try-specific costs to derive the costs of the protease inhibitor combinations.
 
†
 
At the time of model development, nelfinavir was not licensed for sale in Ger-
many, Italy, or Spain. Equal weighting used to derive the cost of the protease
inhibitor combination.
ddl, didanosine; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevi-
rapine; ZDV, zidovudine.
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February 1998). Ex-factory prices were used for
the four European countries because nevirapine
was not yet licensed at the time of the develop-
ment of this model. In the US model, average
wholesale prices, derived from the US Red Book
[37], were used for all drugs except nelfinavir.
Because nelfinavir was not approved for use at
the time of the 1997 Red Book’s [37] publication,
the price given at the time of FDA approval was
used [38]. The daily dosage for nevirapine is two
200-mg tablets with daily costs of US$6.88, FF49,
DM12.85, 15,000 lire, and 1089.15 ptas.
To ensure comparability across the five coun-
tries, all costs were standardized to the second
quarter of 1997, using the country-specific All-
Items Consumer Price Index [39]. (More current
figures were not available for all five countries at
the time of model development.) The Medical
Care Component of the Consumer Price Index
[40] was used for the American model. Estimates
are presented in the local currency of each coun-
try. SAS statistical analysis software, versions
6.11/6.12 (SAS Institute, Cary, NC), was em-
ployed to analyze all clinical trial data. Excel
spreadsheet software (Microsoft Corporation, Red-
mond, WA) was used to estimate the results for
the two models.
 
Sensitivity Analyses
 
Economic models, including cost-effectiveness
models, by their nature provide estimates that in-
corporate uncertainty about the true costs and
clinical effectiveness and uncertainty about the
model structure [41]. Sensitivity analysis provides
a systematic evaluation of the effects of these un-
certainties. In the present analysis, the robustness
of the models to the structural modifications made
and the country-specific parameters used is as-
sessed with a series of sensitivity analyses similar
to those employed by Chancellor et al. [16]. For
each of the five countries, sensitivity analyses were
conducted on three key parameters—timing of
therapy initiation, duration of therapy, and dis-
count rate.
Despite the recommendation that antiretrovi-
ral therapy be initiated before significant immuno-
suppression occurs [4,5], it is important to under-
stand the potential effect of beginning therapy at
different stages of the disease. Some physicians
may prescribe nevirapine triple combination ther-
apy for individuals with significant immunosup-
pression, while others may prescribe this therapy
for those who have received antiretroviral therapy
previously. The effects on costs and outcomes of
beginning treatment in individuals with significant
damage to the immune system and as a rescue
therapy (i.e., therapy when other treatments have
failed) were estimated, beginning the entire patient
cohort in the low CD4 and AIDS health states. To
evaluate the model’s sensitivity to the duration of
the effect of nevirapine, two alternative scenar-
ios—a more optimistic scenario of 30 months [8]
and a more pessimistic one using 15 months—
were employed.
Because policy-makers vary in how they value
costs and outcomes that occur in the present com-
pared to those that accrue in the future, it is neces-
sary to adjust the results of the model using a dis-
 
Table 4
 
Annual drug and health-state costs (1997 values) used in the long-term cost-effectiveness models, by country
 
Average annual costs (in local currency)
Italy (
 

 
1000 lire)
Type of cost France (FF) Germany (DM) Base case Spanish rates Spain (Ptas) US (US$)
Annual drug therapy costs*
ZDV 
 

 
 ddI 27,203 8,549 5,809 — 675,812 5,753
NVP 
 

 
 ZDV 
 

 
 ddI 45,088 16,240 11,284 — 1,073,352 8,264
Protease inhibitor 
 

 
 2 NRTIs
 
‡
 
47,232 17,332 12,562 — 2,582,936 11,504
Annual health state costs
 
†
 
CD4 
 

 
500 cells/mm
 
3
 
7,906 2,336 2,546 3,050 196,328 1,570
High CD4: CD4 
 

 
200 and 
 

 
500 cells/mm
 
3
 
15,812 4,672 5,092 6,100 392,656 3,140
Low CD4: CD4 
 

 
200 cells/mm
 
3
 
26,348 7,780 8,484 10,165 654,256 5,232
AIDS 89,576 26,456 28,844 34,559 2,224,368 17,784
 
*Because nevirapine was not yet marketed in the four European countries, ex-factory prices (obtained from Boehringer Ingelheim operating units in each country)
were employed. For the United States, prices were derived from the 1997 U.S. Red Book [37].
 
†
 
Costs were derived from Chancellor et al. [16] as described in the Methods section.
 
‡
 
Weighted combination of the costs of existing protease inhibitor triple combination therapies.
Cost figures reported in 1997 local currency. Cost figures were inflated using the country-specific All-Items Consumer Price Index reported by the Organization
for Economic Cooperation and Development Main Economic Indicators [39], or in the case of the United States, the Medical Care Component of the Consumer
Price Index [40].
ddI, didanosine; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; ZDV, zidovudine.
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count rate. However, disagreement persists about
whether it is appropriate to discount both costs
and outcomes (in this case, years of life saved)
[42,43] and which discount rate to use [43]. In the
base case, both costs and outcomes that occur af-
ter the first year are discounted at 3% per annum.
Alternatively, the model was reestimated using no
discount rate for either costs or outcomes and by
discounting both costs and outcomes by 1%, 5%,
and 7% per annum as recommended by Lipscomb
et al. [43].
Because the Italian healthcare system currently
is undergoing major healthcare reforms, and even
with the incorporation of the Italian DRG costs
provided by Boehringer Ingelheim Italia s.p.a.
(January 1998), the care algorithms and unit costs
derived earlier by Simpson and LaVallee [12] may
underestimate the current costs of HIV/AIDS care
in Italy. Consequently, the Italian model was rees-
timated using a set of cost estimates based on
HIV/AIDS hospital admission rates in Spain, a
country generally believed to have disease epide-
miology and treatment practices similar to those
observed in Italy.
 
Results
 
The Impact of Adding Nevirapine to ZDV/ddl Dual 
Therapy in the Short Term
 
The burden of opportunistic disease and death is
greater for dual combination therapy than for tri-
ple combination therapy with nevirapine (Table
5). Treatment with triple combination therapy
would prevent 28.5% of opportunistic disease
events and 20.5% of deaths compared to dual
therapy. A reduction in the projected cost of care
(e.g., hospitalization, clinic visits, drugs), exclusive
of the cost of nevirapine, accompanies this im-
provement in survival and reduction in disease
burden. For the first year, the projected savings in
medical care costs represent cost-offsets of 75.2%
(Italian base case) to 175.5% (United States) of
the annual cost of treatment with nevirapine (Ta-
ble 6) for a group of patients similar to those en-
rolled in the ACTG 241 trial. After adjustment for
economic bias in the ACTG 241 baseline data, the
use of nevirapine triple therapy would be expected
to result in 23.1% and 18.3% fewer opportunistic
disease events and deaths, respectively. Projected
cost-offsets then would range from 60.9% (Italian
base case) to 142.1% (United States).
Base case costs likely underestimate the current
costs of HIV/AIDS care in Italy, given the ongoing
healthcare system reforms; however, more recent
unit costs were not available at the time of model
development. Consequently, the model was reesti-
mated assuming that admission rates in Italy would
be similar to those observed in Spain, where the
healthcare system faces comparable disease epide-
miology and has similar treatment patterns. Under
this new scenario, medical care savings increase to
4823 (
 

 
1000) lire per patient, representing 88.1%
of the annual total cost of treatment with nevirap-
ine. After adjusting for the economic bias present
in the ACTG 241 data, projected costs savings
would be expected to decline to 3907 (
 

 
1000) lire
per patient, representing an offset of 71.4% of the
nevirapine treatment cost.
 
Long-Term Cost-Effectiveness of Nevirapine Triple 
Combination Therapy
 
Total costs, survival, and incremental cost-effec-
tiveness ratios (reported in local currency and US
dollars per life-year saved) for each country are re-
ported in Table 7. Under base case assumptions,
100 individuals initially treated with nevirapine
triple combination therapy would be expected to
survive for a total of 1050 years, a cumulative sur-
vival increase of 42.4 years compared to ZDV/ddl
dual therapy. The cost in US dollars per life-year
ranges from $8,831 (Spain) to $17,702 (Germany)
per additional life-year saved (1997 average cur-
rency conversion rates—1.73 DM 
 

 
 US$1; 146.36
ptas 
 

 
 US$1; 5.84 FF 
 

 
 US$1; 1703 lire 
 

 
 US$1)
[44]. These ratios all are less than the US$50,000
per life-year saved (or per quality-adjusted life-
 
Table 5
 
Number of opportunistic diseases events and deaths for a 100-person cohort* receiving dual and triple combination 
therapy
 
France/Germany Italy/Spain United States
Outcomes Dual Triple Dual Triple Dual Triple
Opportunistic disease events 107.8 77.0 109.5 78.3 110.1 78.7
Deaths 13.1 10.4 13.1 10.4 13.1 10.4
 
*The cohort includes 100 HIV-infected adults who had CD4 cell counts of 
 

 
350 cells/mm
 
3
 
 and who had at least 6 months of prior treatment with nucleoside
reverse transcriptase inhibitors.
Dual, zidovudine/didanosine dual therapy; Triple, nevirapine/zidovudine/didanosine triple therapy.
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year saved) value that the field has come to as-
sume as an appropriate cost-effectiveness criterion
for developed countries.
Subjecting the five country-specific models to a
battery of sensitivity analyses reveals patterns sim-
ilar to those presented by Chancellor et al. [16]
(Table 8). The models were most sensitive to the
timing of therapy initiation and therapy duration.
With the exception of the Spanish model, scenar-
ios in which therapy was begun at a later stage
(i.e., all individuals in either the low CD4 health
state or with AIDS) yielded substantially higher
cost-effectiveness ratios; these ratios, ranging from
US$60,779 in Germany to US$66,549 in Italy,
slightly exceed the threshold of US$50,000 per
life-year saved. In the Spanish model, nevirapine
triple therapy was dominant, resulting in better
survival at a slightly lower cost than dual combi-
nation therapy when therapy was begun in indi-
viduals having 200 CD4 cells/mm3. These find-
ings provide an economic rationale to reinforce
the recommendation that antiretroviral therapy
should begin before substantial immunocompro-
mise occurs [4,5]. Shortening or lengthening the
duration of the effect of nevirapine triple combi-
nation therapy resulted in moderate changes in the
model results. Reducing the mean duration of ef-
fect to 18 months yielded higher incremental cost-
effectiveness ratios in each of the five countries,
while increasing the duration by a half year (to 30
months) resulted in lower ratios. Employing the
health-related quality-of-life adjustments devel-
oped by Freedberg et al. [45], the incremental
cost-effectiveness ratios become slightly higher; in
the US base case, the ratio is US$15,012. If the
cost of HAART (of which the nevirapine triple
combination therapy is one regimen) increases to
more than US$36,000 per year (i.e., the annual
cost more than quadruples), the triple combina-
tion therapy is no longer cost-effective, assuming a
threshold of US$50,000 per life-year saved.
The Italian model demonstrated little sensitivity
to cost estimates based on Spanish admission pat-
terns. Only a slight increase from 28,066 (1000)
lire per life-year saved to 28,391 (1000) lire per
life-year saved was predicted. Two patterns of sen-
sitivity were observed when costs and benefits
were discounted at 0%, 1%, 5%, and 7%; the
base case scenario discounts both at 3% [43]. For
Spain and the United States, the incremental cost-
Table 7 Base case* costs, survival, and incremental cost-
effectiveness ratios comparing nevirapine triple combination 
therapy to zidovudine/didanosine dual therapy, by country
Incremental cost-
effectiveness ratio
Country/therapy Costs Survival LC/LY† US$/LY‡
France
Dual therapy 77,041,857 1,007.8
Triple therapy 81,326,501 1,050.2 101,057 17,306
Germany
Dual therapy 26,179,948 1,007.8
Triple therapy 27,481,966 1,050.2 30,709 17,702
Italy
Dual therapy 22,102,242 1,007.8
Triple therapy 23,292,195 1,050.2 28,066§ 16,472
Spain
Dual therapy 3,159,084 1,007.8
Triple therapy 3,213,959 1,050.2 1,294§ 8,831
United States
Dual therapy 17,218,891 1,007.8
Triple therapy 17,826,815 1,050.2 14,338 —
*Base case scenario as described in Methods section.
†Incremental cost-effectiveness ratios are reported as local currency (LC) per
life-year (LY) saved. All costs are reported in 1997 currency values.
‡Incremental cost-effectiveness ratios are reported as United States dollars
(US$) per life-year (LY) saved. Currency exchange rates for 1997 are as fol-
lows: 1.73 DM  US$1; 146.36 ptas  US$1; 5.84 FF  US$1; 1,703 lire 
US$1 [44].
§Italian and Spanish ratios are reported 1000 lire/life-year and 1000 ptas/
life-year, respectively.
Table 6 Projected 1-year treatment costs and cost-offsets in 1997 local currency, by country
Medical care savings (in LC)† % offset‡
Country NVP cost/year (in LC)* Unadjusted Adjusted§ Unadjusted Adjusted§
France (FF) 17,885 24,381 19,749 136.3 110.4
Germany (DM) 4,691 4,664 3,778 99.4 80.5
Italy (1000 lire)
Base case 5,475 4,116 3,334 75.2 60.9
Spanish rates 5,475 4,823 3,907 88.1 71.4
Spain (1000 ptas) 398 362 293 91.0 73.7
United States (US$) 2,511 4,406 3,569 175.5 142.1
*Cost per year calculated as the country-specific price per day multiplied by 365 days.
†Projected 1-year cost savings per patient attributable to nevirapine triple combination therapy.
‡Proportion of treatment costs offset by the use of nevirapine triple combination therapy (calculated as the medical care savings divided by the 1-year costs of ther-
apy with nevirapine).
§Adjusted for the economic bias at baseline (ACTG 241) [6].
NVP, nevirapine; LC, local currency; DM, German Deutschemarks; FF, French francs; lire, Italian lire; ptas, Spanish pesetas; US$, United States dollars.
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effectiveness ratios become smaller as the discount
rate increases. In the French, German, and Italian
models, the incremental cost-effectiveness ratios
become larger as the discount rate increases be-
cause the incremental survival declines at a slightly
more rapid rate than incremental costs in these
countries.
Discussion
This study, unlike those conducted during the past
decade [10–17], estimates both the short- and long-
term health benefits and economic performance of
nevirapine triple therapy in five countries. The
crossnational comparison, like that used by Simp-
son et al. [15] and Kempel et al. [11], captures
country differences in epidemiological patterns,
treatment practices, and reimbursement/regulatory
strategies, providing decision-makers with the in-
formation critical to understanding the added value
of nevirapine triple combination under different
healthcare systems.
For each country, the models predict that nevi-
rapine triple therapy provides superior health out-
comes compared to ZDV/ddI dual therapy in the
short term and is cost-effective in the long term.
One hundred patients with a risk profile similar to
those enrolled in the INCAS 1046 clinical trial
may expect 34 fewer AIDS-related opportunistic
disease events or deaths during the first year of
therapy than patients treated with dual therapy.
Examining the health benefits in the longer term
suggests that overall survival would increase as
well. Concomitantly, both short- and long-term
budgetary implications arise as a result of the pre-
dicted improvement in health status.
In each of the five countries modeled, a sizeable
proportion of the annual costs of nevirapine ther-
apy (ranging from 60.9% to 142.1% after adjust-
ment for baseline bias in the ACTG 241 clinical
trial data) is offset by the expected savings in hos-
pital care, medical visits, specialist consults, and
medicines, all of which would be unnecessary
given the predicted improvement in health status.
Differences in treatment patterns (e.g., intensity
and types of care provided) and medical care pro-
duction costs affect the magnitude of the short-
term medical care savings expected with the addi-
tion of an effective new therapy. As expected,
these cost savings and cost-offsets are greater in
healthcare systems that employ relatively more in-
tensive types of care or where medical care pro-
duction costs are higher (e.g., the United States)
and lower in countries where treatment practices
rely on less expensive types of care (e.g., Italy and
Spain). A comparison of the net incremental cost
(i.e., cost of the drug minus the expected cost sav-
ings) of adding nevirapine in each country reveals
results similar to those of Anis et al. [17], who
report net incremental costs ranging from Can
$2567 to Can$2648. Incremental costs for nevi-
rapine therapy range (reported in 1996 Canadian
dollars) from Can$1201 (unadjusted Italian base
case) to Can$2582 (unadjusted American base
case). (1996 currency conversion rates: 1Can$ 
Table 8 Incremental cost-effectiveness ratios of nevirapine triple therapy compared with zidovudine/didanosine therapy: 
sensitivity analysis results, by country
Incremental cost-effectiveness ratios (in LC/LY)
Scenario France Germany Italy* Spain* United States
Spanish admission rates† — — 28,397 — —
Time of therapy initiation‡
All with low CD4 386,155 105,147 113,333 Dominated§ 41,747
All with AIDS 219,246 57,175 68,248 1,634 28,182
Duration of nevirapine therapy 
18 months 125,156 37,729 36,136 3,251 20,886
30 months 76,263 23,980 20,330 596 10,272
Discount rate
0% 94,542 29,357 26,506 1,888 15,349
1% 96,305 29,831 26,911 1,702 15,001
5% 107,687 32,038 29,753 836 3,740
7% 116,498 33,894 32,061 324 13,232
*Italian and Spanish ratios are reported 1000 lire/life-year and 1000 ptas/life-year, respectively.
†Costs are adjusted to reflect Spanish hospital admissions rates.
‡All 100 individuals in the cohort begin therapy in the described health state.
§The triple combination therapy (nevirapine/zidovudine/didanosine) is said to dominate the dual therapy (zidovudine/didanosine) because it costs less and provides
improved survival.
Duration of effect is the number of months required for CD4 cell counts to return to baseline.
Incremental cost-effectiveness ratios are reported as local currency (LC) per life-year (LY) saved. All costs are reported in 1997 currency values.
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1.10 DM; 1Can$  3.75FF; 1Can$  92.87 ptas;
1Can$  1131.38 lire; 1Can$  0.73 US$.)
To place the results of the lifetime cost-effec-
tiveness model into context, it is helpful to com-
pare our incremental cost-effectiveness ratios with
those reported for other types of HIV drug ther-
apy. Early cost-effectiveness analyses of HIV mono-
therapies reported incremental cost-effectiveness
ratios (in 1991 US$) ranging from US$6,553 to
US$70,526 per life-year saved [13,43]. Studies of
dual combination therapy [15,16] suggest ratios
ranging from US$12,000 to US$20,000 per life-
year saved. The study by Chancellor et al. [16], on
which our long-term model is based, found an in-
cremental cost-effectiveness ratio of US$10,311,
or £6,276, for adding lamivudine to ZDV mono-
therapy. Most recently, Anis et al. [17] estimated
that the first-year incremental cost-effectiveness
ratios of adding a protease inhibitor to antiretro-
viral therapy might range from Can$10,481 to
Can$98,074 per life-year gained (reported in 1996
Canadian dollars) or US$7,809 to US$73,067
(1997Can$  1.015859 1996Can$; 1 Can$ 
0.733389US$, 1996 average value). Cook et al.
[46] report an incremental cost-effectiveness ratio
of US$13,229 per life-year at 20 years for the ad-
dition of the protease inhibitor indinavir to dual
combination therapy. Further, our results com-
pare favorably to prophylaxis for Pneumocystis
carinii pneumonia (US$16,000 per quality-adjusted
life-year saved) [45] and with the thresholds pro-
mulgated by Laupacis et al. [47]. Even for the
most sensitive parameter (i.e., time of therapy ini-
tiation), the incremental cost-effectiveness ratios
for the five countries are only slightly higher than
US$50,000 per life-year.
The reported results should be interpreted cau-
tiously, recognizing that the models are based on
current knowledge. As seen in the sensitivity anal-
yses, the long-term model results were sensitive to
the duration of the therapeutic effect of nevirap-
ine. If triple therapy does not delay viral break-
through as long as assumed in the models, then
the models may overestimate the cost-effectiveness
of nevirapine triple therapy. However, Montaner
et al. [8] report that 69% of INCAS 1046 patients
who were followed for more than 30 months (6
months longer than assumed in this model) had
undetectable levels of virus. The model’s base case
assumption of nevirapine therapy duration likely
is reasonable given current data. The estimated
duration of protease inhibitor therapy and the as-
sumption of declining effect for subsequent pro-
tease inhibitor therapy are based on the prelimi-
nary results of several studies [25,27–33]. Recently,
Gulick et al. [26] reported that 66% of patients re-
ceiving indinavir, zidovudine, and lamivudine for
100 weeks had viral levels less than 50 copies/ml,
suggesting that the duration of effect may be
longer than that assumed in this model. The im-
pact of uncertainties in the duration of effect for
the protease combination probably would be dis-
tributed similarly between the dual and triple ther-
apy arms, with little anticipated effect on the in-
cremental cost-effectiveness ratio for nevirapine
triple therapy.
The model results are those predicted for the
addition of nevirapine to two particular nucleo-
side reverse transcriptase inhibitors, zidovudine
and didanosine. The present comparators were se-
lected on the basis of available clinical trial data;
however, together they represent only one of the
many possible combinations that can be used as
part of the recommended therapy guidelines [4,5].
The preliminary results of two recent studies [48,49]
indicate that nevirapine in combination with other
nucleoside reverse transcriptase inhibitor dyads
are as effective in reducing viral load as the combi-
nation used in this model. Therefore, repetition of
these models with different therapy dyads likely
would produce similar results.
Resource use data for the short-term model
were derived from consensus panels composed of
a small number of expert physicians from each of
the five countries [12,15]. Although an attempt
was made to achieve geographic representation, it
is possible that other experts might specify differ-
ent mixes of resource use and treatment patterns.
Also, treatment patterns may have changed since
the panels were conducted (1995–1996) and the
mix of resources and the costs of care may be dif-
ferent now. If the country-specific care costs are
less than those used in the model, the economic
benefits of nevirapine triple therapy may be over-
estimated.
Also, Italian healthcare reform efforts made it
difficult to obtain accurate costs in that country.
Although the available DRG costs were employed
in the model, many of the DRGs do not corre-
spond directly to all the opportunistic disease
events in the model, and in some cases, the DRGs
include conditions that are not AIDS related.
Thus, it is unclear whether the Italian DRGs re-
flect appropriate treatment patterns for the ODEs.
The attempt to correct for the DRG resource mix-
tures by using Spanish hospital admissions pat-
terns had relatively little effect on the results of ei-
ther the short-or long-term models. As additional
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cost and resource mix data become available in It-
aly, it may be prudent to reestimate these models.
Country-specific costs employed in the long
term model were estimated by adjusting the health-
state-specific costs from Chancellor et al. [16] us-
ing conversion rates derived from Simpson et al.
[15] and Simpson and LaVallee [12]. The cost
data in the Chancellor et al. [16] model represent
the costs and treatment patterns within a single in-
stitution (Chelsea and Westminster Hospital in
London) for a cohort of patients treated in 1994–
1995. To the extent that treatment patterns have
changed over time, the costs of care for opportu-
nistic disease events may be different from those
used.
The models do not specifically take into ac-
count the costs of adverse events associated with
nevirapine or with the protease inhibitor combina-
tions; these costs are assumed to be included in the
health-state costs used. If side effects with nevi-
rapine are much more costly than those of other
combinations, then the costs of caring for these
events may reduce the predicted medical care sav-
ings and cost offsets. To the extent that adverse
events are similar and that their costs are small
compared to the costs of providing care for oppor-
tunistic disease, these costs likely would have little
effect on the incremental cost-effectiveness ratios.
Finally, the value of earnings forgone as the result
of HIV-related illness and premature death are ex-
cluded; only the costs of direct medical care are
used in the models.
As the costs of HIV/AIDS care increase and re-
sources become increasingly constrained, the deci-
sion to fund competing new therapy options will
become more difficult. Government policy-makers
and private payers will require information about
the value for money of these therapies. Modeling,
despite its limitations, can contribute to the needed
information. The results of the present analysis
provide administrators and decision-makers in the
five countries some evidence that the added value
of triple combination therapy with nevirapine, zi-
dovudine, and didanosine falls within our expec-
tations for cost-effective therapies in developed
countries. They also support findings from previ-
ous studies [12,15] that the first-year cost-offset
for a therapy depends on the cost structure of the
care system. Further, this study demonstrates that
it is possible to recycle well-constructed and docu-
mented cost-effectiveness models of antiretroviral
therapy, and use them to gain insight into the fac-
tors that affect efficiency across countries and an
understanding of the need to evaluate both short-
and long-term economic forecasts when assessing
antiretroviral therapies.
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